ICD-11 code 2E65.0 refers to lobular carcinoma in situ of the breast. This particular code is used in the healthcare industry to classify and document cases of non-invasive breast cancer that originates in the lobules of the breast. Lobular carcinoma in situ is considered to be a pre-invasive condition that may slightly increase the risk of developing invasive breast cancer in the future.
Patients diagnosed with lobular carcinoma in situ do not typically experience symptoms such as lumps or breast pain. Instead, this condition is often detected through routine mammograms or other imaging tests. Treatment options for lobular carcinoma in situ may include careful monitoring, hormonal therapy, or in some cases, a surgical procedure to remove the affected area of breast tissue. It is important for patients with this diagnosis to consult with their healthcare providers to determine the most appropriate course of action.
Table of Contents:
- #️⃣ Coding Considerations
- 🔎 Symptoms
- 🩺 Diagnosis
- 💊 Treatment & Recovery
- 🌎 Prevalence & Risk
- 😷 Prevention
- 🦠 Similar Diseases
#️⃣ Coding Considerations
The SNOMED CT code equivalent to the ICD-11 code 2E65.0 for Lobular carcinoma in situ of the breast is 1089571000000101. This code is used to specify the particular condition of lobular carcinoma present in the breast tissue. SNOMED CT is a comprehensive and standardized terminology that is widely used in healthcare to accurately represent clinical concepts and facilitate interoperability among different electronic health record systems. The transition from ICD-11 to SNOMED CT allows for a more detailed and precise classification of diseases and conditions, providing healthcare professionals with more specific and standardized terminology for documentation and data exchange. Using SNOMED CT codes helps to improve the accuracy and efficiency of data recording and sharing in the healthcare industry, ultimately leading to better patient care and outcomes.
In the United States, ICD-11 is not yet in use. The U.S. is currently using ICD-10-CM (Clinical Modification), which has been adapted from the WHO’s ICD-10 to better suit the American healthcare system’s requirements for billing and clinical purposes. The Centers for Medicare and Medicaid Services (CMS) have not yet set a specific date for the transition to ICD-11.
The situation in Europe varies by country. Some European nations are considering the adoption of ICD-11 or are in various stages of planning and pilot studies. However, as with the U.S., full implementation may take several years due to similar requirements for system updates and training.
🔎 Symptoms
Symptoms of lobular carcinoma in situ of the breast, classified under code 2E65.0 in medical records, typically do not produce any visible signs or physical symptoms that can be detected through a physical examination. As a non-invasive form of breast cancer, the condition is characterized by abnormal cells developing within the lobules of the breast, but these cells do not penetrate through the lobule walls or spread to surrounding breast tissue. Without an imaging test or biopsy, lobular carcinoma in situ is usually asymptomatic and may only be detected incidentally during a mammogram or other diagnostic procedure. While individuals with lobular carcinoma in situ may not experience any pain, lumps, or changes in breast appearance, the condition is still considered a risk factor for developing invasive breast cancer in the future.
Due to the lack of noticeable symptoms associated with lobular carcinoma in situ, early detection and diagnosis rely heavily on screening mammography and routine breast examinations for identifying abnormal cell growth within the lobules of the breast tissue. As a non-palpable condition that does not present any visible changes or physical manifestations, individuals with lobular carcinoma in situ may not experience pain, discomfort, or swelling in the affected breast. However, medical professionals recommend regular breast cancer screenings, including mammograms, to monitor any changes in breast tissue and detect potential abnormalities at an early stage. While lobular carcinoma in situ is not considered a form of invasive breast cancer, its presence may necessitate further evaluation and treatment to reduce the risk of developing invasive breast cancer in the future.
In cases where lobular carcinoma in situ progresses to invasive breast cancer, individuals may begin to experience symptoms such as breast lump or mass, changes in breast size or shape, breast pain or tenderness, nipple discharge other than breast milk, and skin changes on the breast, including redness, dimpling, or scaliness. These symptoms are more commonly associated with invasive breast cancer, where abnormal cells have spread beyond the lobules and invaded surrounding breast tissue. Early detection and prompt medical intervention are crucial in managing lobular carcinoma in situ and preventing its progression to invasive breast cancer, highlighting the importance of regular breast screenings and follow-up care for individuals at risk of developing breast cancer.
🩺 Diagnosis
Diagnosis of lobular carcinoma in situ of the breast, coded as 2E65.0 in the ICD-10 system, typically involves a combination of imaging studies, clinical examination, and tissue biopsy. Mammography is the primary imaging modality used to detect abnormalities in breast tissue, including the presence of small calcifications or subtle architectural distortions that may indicate the presence of a non-invasive carcinoma such as LCIS.
Clinical breast examination by a healthcare provider may reveal no physical signs of the disease, as LCIS often does not cause any symptoms or palpable lumps. However, if a suspicious area is detected during physical examination or imaging studies, the patient may be referred for a breast biopsy to obtain a tissue sample for further evaluation. Biopsy procedures may involve a core needle biopsy, where a small tissue sample is extracted using a hollow needle, or a surgical biopsy for larger tissue samples.
Once a tissue biopsy is obtained, the pathologist will examine the cells under a microscope to determine if they show the characteristic features of lobular carcinoma in situ. The cells of LCIS usually appear uniform and monotonous, with characteristic small, round nuclei and abundant cytoplasm. The presence of these features, along with additional molecular tests such as immunohistochemistry to detect hormone receptor status, can confirm the diagnosis of LCIS and guide treatment decisions.
💊 Treatment & Recovery
Treatment for 2E65.0 (Lobular carcinoma in situ of the breast) typically involves close monitoring or observation, as it is considered a non-invasive form of breast cancer. In some cases, medical professionals may recommend a more aggressive approach such as surgery to remove the affected tissue.
Surgical options for treating lobular carcinoma in situ may include a lumpectomy to remove the affected area of the breast, or a mastectomy to remove the entire breast. Radiation therapy may also be used following surgery to reduce the risk of recurrence. It is important for individuals with this diagnosis to discuss treatment options with their healthcare team to determine the most appropriate course of action for their specific situation.
Recovery from treatment for lobular carcinoma in situ of the breast may vary depending on the type of treatment received and the individual’s overall health. Following surgery, patients may experience some discomfort and have restrictions on physical activity for a period of time. It is important for individuals to follow their healthcare team’s recommendations for post-operative care and attend follow-up appointments to monitor their recovery and ensure the effectiveness of treatment.
🌎 Prevalence & Risk
Lobular carcinoma in situ of the breast, coded as 2E65.0 in the ICD-10 system, is a non-invasive form of breast cancer that begins in the lobules of the breast. In the United States, lobular carcinoma in situ accounts for approximately 15% of all cases of ductal and lobular breast carcinoma. The prevalence of this condition is estimated to be around 60,000 new cases diagnosed each year in the United States.
In Europe, the prevalence of lobular carcinoma in situ varies by country, but overall it is considered to be less common than ductal carcinoma in situ. However, the incidence of lobular carcinoma in situ has been steadily rising in Europe over the past few decades. It is estimated that approximately 20,000 new cases of lobular carcinoma in situ are diagnosed in Europe each year.
In Asia, the prevalence of lobular carcinoma in situ of the breast is not well documented, and data on the incidence of this condition in Asian countries is limited. However, studies have shown that the prevalence of lobular carcinoma in situ may be lower in Asian populations compared to Western populations. Further research is needed to fully understand the prevalence of this condition in Asia.
In Australia, lobular carcinoma in situ of the breast is believed to account for 10-15% of all cases of in situ breast cancer. The incidence of lobular carcinoma in situ in Australia is similar to that in the United States, with an estimated 60,000 new cases diagnosed each year. The prevalence of this condition in Australia has been increasing over the past few decades, likely due to improved detection methods and increased awareness of breast cancer screening.
😷 Prevention
To prevent 2E65.0 (Lobular carcinoma in situ of the breast), individuals should be aware of the risk factors associated with the disease. Factors such as age, family history of breast cancer, hormonal factors, and genetic mutations like BRCA1 and BRCA2 can increase the likelihood of developing lobular carcinoma in situ. By understanding these risk factors, individuals can take proactive steps to lower their risk and potentially prevent the disease.
Regular screening and early detection are essential in preventing 2E65.0. Mammograms and breast exams can help detect abnormalities in the breast tissue, allowing for early intervention if any issues are found. It is recommended that women over the age of 40 receive regular mammograms to screen for breast cancer, including lobular carcinoma in situ. By catching the disease early, it can be treated more effectively and may prevent it from progressing to a more advanced stage.
Maintaining a healthy lifestyle can also play a role in preventing 2E65.0. Eating a balanced diet, exercising regularly, maintaining a healthy weight, limiting alcohol consumption, and avoiding smoking can all help reduce the risk of developing breast cancer, including lobular carcinoma in situ. By adopting these healthy habits, individuals can support their overall health and potentially lower their risk of developing this disease.
🦠 Similar Diseases
One similar disease to 2E65.0 is ductal carcinoma in situ (DCIS) of the breast. This condition is characterized by the presence of abnormal cells inside the milk ducts of the breast. The cells have not spread beyond the ducts into surrounding breast tissue. The ICD-10 code for DCIS is 2E66.0.
Another related disease is atypical ductal hyperplasia (ADH) of the breast. ADH is a benign condition where there is an overgrowth of cells in the breast ducts that appear abnormal but have not yet become cancerous. It is considered a marker for an increased risk of developing breast cancer in the future. The ICD-10 code for ADH is D05.10.
A third disease similar to lobular carcinoma in situ is atypical lobular hyperplasia (ALH) of the breast. ALH is a benign condition where there is an overgrowth of cells in the lobules (milk-producing glands) of the breast that appear abnormal but have not become cancerous. Like ADH, ALH is also considered a marker for an increased risk of developing breast cancer. The ICD-10 code for ALH is D05.80.
Lastly, flat epithelial atypia (FEA) is another disease that is related to lobular carcinoma in situ. FEA is a benign condition characterized by atypical flat epithelial cells lining the breast ducts. These cells are not cancerous but are considered a marker for an increased risk of developing breast cancer. The ICD-10 code for FEA is D05.80.